GLAXOSMITHKLINE PLC Form 6-K April 19, 2017
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 19 April 2017
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')
Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

b) Position/status Chief Executive Officer

Initial notification/

amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of

dividends paid to

b) Nature of the transaction shareholders on 13 April 2017 on Ordinary Shares held

in the Company's Deferred

Investment Award Programme.

c) Price(s) and volume(s)
Price(s) Volume(s)
£16.39 575.028
d) Aggregated information n/a (single transaction)

Aggregated volume Price

2017-04-13

Place of the transaction n/a Details of PDMR/person closely associated with them ('PCA') Name Mr R G Connor President, Global b) Position/status Manufacturing & Supply Initial notification/ c) Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') Description of the financial instrument ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April b) Nature of the transaction 2017, on Ordinary Shares held in the Company's Deferred Investment Award Programme. Price(s) Volume(s) c) Price(s) and volume(s) £16.39 230.011 n/a (single transaction) Aggregated information d) Aggregated volume Price Date of the transaction 2017-04-13 Place of the transaction f) n/a 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr S A Hussain President, Global b) Position/status Pharmaceuticals Initial notification/ c) Initial notification amendment

e) Date of the transaction

Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') Description of the financial instrument ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April b) Nature of the transaction 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme. Price(s) Volume(s) Price(s) and volume(s) 287.514 £16.39 n/a (single transaction) Aggregated information d) Aggregated volume Price Date of the transaction 2017-04-13 Place of the transaction f) n/a 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr B McNamara CEO, GSK Consumer b) Position/status Healthcare Initial notification/ c) Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc 5493000HZTVUYLO1D793 b) LEI Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument GlaxoSmithKline plc

American Depositary Shares

('ADSs')

ISIN: US37733W1053 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13

b) Nature of the transaction

April 2017 on ADSs held in the Company's Deferred Investment Award Programme.

c) Price(s) and volume(s)

Price(s) Volume(s) \$41.8150 359.648 n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

Date of the transaction 2017-04-13

Place of the transaction f) n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern

b) Position/status Chief Strategy Officer

Initial notification/

Initial notification amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument

each ('Ordinary Shares')

ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following

the re-investment of dividends paid to

shareholders on 13 April b) Nature of the transaction

2017 on Ordinary Shares held in the Company's Deferred

Investment Award

Programme.

Price(s) Volume(s) c) Price(s) and volume(s) £16.39 230.011

n/a (single transaction)

Aggregated information d) Aggregated volume Price e) Date of the transaction 2017-04-13 Place of the transaction f) n/a 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms C Thomas b) Position/status Senior Vice President, HR Initial notification/ Initial notification amendment Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted Ordinary shares of 25 pence each ('Ordinary Shares') Description of the financial instrument ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April b) Nature of the transaction 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme. Price(s) Volume(s) c) Price(s) and volume(s) £16.39 230.011 n/a (single transaction) Aggregated information d) Aggregated volume Price Date of the transaction 2017-04-13 Place of the transaction f) n/a

Details of PDMR/person closely associated with them ('PCA')
 Name Dr P J T Vallance

6

President, R&D b) Position/status

Initial notification/

c) Initial notification amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

Description of the financial instrument

each ('Ordinary Shares')

ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following

the re-investment of dividends paid to

shareholders on 13 April b) Nature of the transaction

> 2017 on Ordinary Shares held in the Company's Deferred

Investment Award

Programme.

Price(s) Volume(s) c) Price(s) and volume(s) 287.514

£16.39 n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

Date of the transaction 2017-04-13

Place of the transaction f)

n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

> GlaxoSmithKline plc (Registrant)

Date: April 19, 2017

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc